Monoclonalantibodies produced by recombinant dna technology
tisotumab vedotin-tftv (Tivdak from Seagen) is part of the numerous monoclonalantibodies produced by recombinant dna technology in mammalian Chinese hamster ovary (CHO) cells approved by the the fda in 2021. Tivdak is indicated for the treatment of adult patients with recurrent or metastatic cervicalcancer with disease progression on or after chemotherapy. Tisotumab is a human IgG1K antibody composed of two kappa light chains and two IgG1 heavy chains Are you involved […]